Mollie E. Barnard, ScD; Elizabeth M. Poole, PhD; Gary C. Curhan, MD, ScD; et al.
free access
has audio
JAMA Oncol. 2018;4(12):1675-1682. doi:10.1001/jamaoncol.2018.4149
This cohort study uses data from the Nurses鈥 Health Studies to evaluate associations between use of nonsteroidal anti-inflammatory drugs and risk of epithelial ovarian cancer.
-
Podcast:
Analgesic Use and Risk of Ovarian Cancer in the Nurses鈥 Health Studies
-
Editorial
Aspirin and Chemoprevention鈥擧ave We Arrived?
Victoria L. Seewaldt, MD
JAMA Oncol
Tracey G. Simon, MD; Yanan Ma, PhD; Jonas F. Ludvigsson, MD, PhD; et al.
free access
has audio
JAMA Oncol. 2018;4(12):1683-1690. doi:10.1001/jamaoncol.2018.4154
This pooled analysis of the Nurses鈥 Health Study and the Health Professionals Follow-up Study examines the association between long-term use of aspirin and the development of hepatocellular carcinoma in adult men and women.
-
Podcast:
Analgesic Use and Risk of Ovarian Cancer in the Nurses鈥 Health Studies
-
Editorial
Aspirin and Chemoprevention鈥擧ave We Arrived?
Victoria L. Seewaldt, MD
JAMA Oncol
Xiangchun Li, PhD; Boris Pasche, MD, PhD; Wei Zhang, PhD; et al.
free access
JAMA Oncol. 2018;4(12):1691-1698. doi:10.1001/jamaoncol.2018.2805
This analysis of genomic data from The Cancer Genome Atlas and an Asian cohort investigates associations between MUC16 mutation, tumor mutation load, and survival in patients with gastric cancer.
-
Invited Commentary
MUC16 Mutations and Prognosis in Gastric Cancer: A Little Goes a Long Way
Elizabeth C. Smyth, MB BCh, MSc; Rebecca C. Fitzgerald, MBBChir MD, FRCP, FMedSci
JAMA Oncol
Joseph Sparano, MD; Anne O鈥橬eill, MS; Katherine Alpaugh, PhD; et al.
free access
JAMA Oncol. 2018;4(12):1700-1706. doi:10.1001/jamaoncol.2018.2574
This secondary analysis of a randomized clinical trial investigates the association of circulating tumor cells with recurrence of breast cancer 5 or more years after diagnosis among patients with hormone receptor鈥損ositive breast cancer.
Vaibhav Sahai, MBBS, MS; Paul J. Catalano, ScD; Mark M. Zalupski, MD; et al.
free access
JAMA Oncol. 2018;4(12):1707-1712. doi:10.1001/jamaoncol.2018.3277
This single-arm, 2-stage, phase 2 clinical trial assesses the safety and efficacy of intravenous gemcitabine plus nanoparticle albumin-bound鈥損aclitaxel for treatment of adults with advanced cholangiocarcinoma.
Xuesong Han, PhD; K. Robin Yabroff, PhD; Elizabeth Ward, PhD; et al.
free access
JAMA Oncol. 2018;4(12):1713-1720. doi:10.1001/jamaoncol.2018.3467
This population-based registry study of nonelderly patients with newly diagnosed cancer examines changes in the percentage of uninsured patients and stage at diagnosis before and after implementation of the Patient Protection and Affordable Care Act (ACA).
Daniel Y. Wang, MD; Joe-Elie Salem, MD; Justine V. Cohen, MD; et al.
free access
JAMA Oncol. 2018;4(12):1721-1728. doi:10.1001/jamaoncol.2018.3923
This systematic review and meta-analysis analyzes the incidence of regimen-specific fatal toxic effects associated with the use of immune checkpoint inhibitors for cancer treatment.
Brian H. Kushner, MD; Irene Y. Cheung, ScD; Shakeel Modak, MD; et al.
free access
JAMA Oncol. 2018;4(12):1729-1735. doi:10.1001/jamaoncol.2018.4005
This phase 1 clinical trial examines the escalation and safety of humanized anti-GD2 antibody doses in combination with granulocyte-macrophage colony-stimulating factor for treating patients with high-risk neuroblastoma.
Stacy M. Fischer, MD; Danielle M. Kline, MS; Sung-Joon Min, PhD; et al.
free access
JAMA Oncol. 2018;4(12):1736-1741. doi:10.1001/jamaoncol.2018.4014
This randomized clinical trial investigates if a culturally tailored patient navigator intervention can improve palliative care outcomes for Latino patients with advanced cancer.
Brian C. Baumann, MD; Ioannis I. Verginadis, PhD; Chuan Zeng, PhD; et al.
free access
JAMA Oncol. 2018;4(12):1742-1748. doi:10.1001/jamaoncol.2018.4292
This survey study of patients undergoing radiotherapy for cancer compares clinician advice against using topical agents before radiotherapy to avoid an increased radiation dose to the skin with the results of a dosimetric study and a preclinical study in an animal model.
-
Invited Commentary
Avoiding Topical Agents Before Daily Radiotherapy: Debunking Dogma
Simon A. Brown, MD; Chelsea C. Pinnix, MD, PhD
JAMA Oncol
Aaron J. Grossberg, MD, PhD; Xiudong Lei, PhD; Ting Xu, PhD; et al.
free access
JAMA Oncol. 2018;4(12):1751-1757. doi:10.1001/jamaoncol.2018.2583
This cohort study of female participants with stage 0 to IIA breast cancer treated with breast-conserving surgery and whole-breast irradiation assesses whether radiation-induced toxicities of normal breast tissue 3 years after radiotherapy are associated with the transforming growth factor 尾 gene variant C鈭509T.
Anna Sällfors Holmqvist, MD, PhD; Yanjun Chen, MS; Jessica Wu, MPH; et al.
free access
online only
JAMA Oncol. 2018;4(12):e182453. doi:10.1001/jamaoncol.2018.2453
This cohort study examines cause-specific late mortality among individuals who have lived 2 years or more after allogeneic blood or marrow transplantation performed in childhood and whether rates of late mortality have changed over time.
Chandrajit P. Raut, MD, MSc; N. Joseph Espat, MD; Robert G. Maki, MD, PhD; et al.
free access
online only
JAMA Oncol. 2018;4(12):e184060. doi:10.1001/jamaoncol.2018.4060
This phase 2, multi-institutional clinical trial assesses whether patients with resected primary gastrointestinal stromal tumor receiving 5 years of adjuvant imatinib mesylate therapy have improved recurrence-free survival and overall survival compared with patients receiving a shorter duration of therapy in previous studies.